DELCATH SYSTEMS INC

Company Overview

Delcath Systems Inc. is a healthcare company in the Medical Devices / Medical Equipment space that commercializes a liver-directed drug/device combination centered on percutaneous hepatic perfusion (PHP). Its FDA‑approved product HEPZATO (melphalan with a hepatic delivery system) launched commercially in 2024 for uveal melanoma with hepatic metastases, while the device-only CHEMOSAT system has an established European footprint (>1,700 procedures, 23+ centers). The company sells single‑use procedure kits, trains interventional radiology teams under a U.S. REMS, supports adoption with a growing commercial field organization, and conducts ongoing R&D/clinical programs to expand indications. Manufacturing and distribution are split between Queensbury, NY (critical components) and Galway, Ireland (EU final manufacturing).

Executive Compensation Practices

Given Delcath’s transition from R&D to commercial operations, executive pay is likely shifting toward commercialization and milestone‑driven incentives: key compensation drivers will include product revenue, procedural volumes/number of treating centers, reimbursement milestones (CMS J‑code, NTAP, private payer coverage), and clinical trial readouts that expand label claims. Management already discloses material stock‑based compensation and fair‑value assumptions (warrant/contingent liability models), so executives are likely paid with significant equity-based incentives (options/RSUs and performance awards) to align long‑term value creation and retention of commercial talent. Short‑term cash bonuses or commission/bonus pools may be tied to quarterly sales adoption metrics, while long‑term incentives will track regulatory and indication expansion milestones and overall cash runway metrics given ongoing capital needs.

Insider Trading Considerations

Insider trading in Delcath will be highly event‑sensitive: FDA approvals, publication of Phase 3 FOCUS data, CMS reimbursement decisions (J‑code/NTAP) and meaningful quarter‑over‑quarter procedural adoption updates have historically driven material stock moves and will continue to do so. Because the company is small, has a concentrated insider equity base, and recently used warrants/private placements, insider sales or warrant exercises can have outsized signaling and dilution effects; watch Form 4 filings and any disclosed 10b5‑1 plans. Regulatory and REMS obligations also create natural blackout windows around key clinical and commercial milestones, and SEC Section 16 reporting plus related‑party transactions from financings can provide early warnings of insider liquidity events.